Main Achievements

  • Opened our multi-disciplinary flagship trial, STRASS 2 1 as well as the TOLERANCE 2 trial – both of which are purely academic with EORTC as sponsor. STRASS 2 is a global trial examining the role of neo-adjuvant chemotherapy in high-risk retroperitoneal sarcoma and TOLERANCE is a phase III trial to optimise systemic treatment for sarcoma patients in the elderly.
  • Seeking funding for an investigator-initiated multi-cohort trial to evaluate immunotherapy in soft tissue sarcoma with a translational endpoint. The study may be expanded to other tumour types.
  • Hosted two Group meetings where we explored new strategies to fund academic trials and new approaches to engage commercial partners.


In recent years, EORTC has been involved in a number of large practice-changing clinical trials in the field of Soft Tissue and Bone, leading to the registration of drugs to treat sarcomas including gastrointestinal stromal tumors (GIST). The following compounds were investigated within this group (STBSG):

  • Imatinib for GIST
  • Trabectedin for all types of STS
  • Pazopanib for non-adipocytic STS
  • Eribulin for liposarcomas More information

Multicentre trials, with large patient numbers to influence clinical practice and address important research topics, evaluated the role of adjuvant chemotherapy in soft tissue sarcoma patients as well as the role of single-agent doxorubicin versus the combination of doxorubicin plus ifosfamide in advanced and/or metastatic STS patients.

Related Projects

  • EORTC-1637 (lms retrospective): retrospective evaluation of first-line treatment for advanced, metastatic or unresectable leiomyosarcomas.
    (project leader: lorenzo d’ambrosio)
    Status: database open
    This is a retrospective research project (rp) to evaluate the activity of doxorubicin as monotherapy as well as in combination with ifosfamide or dacarbazine as first-line treatment for leiomyosarcoma, pleomorphic leiomyosarcoma and undifferentiated sarcoma with smooth muscle differentiation, to potentially guide the design of a prospective randomized study.
    As of today, we have already into our database.
    Please be noted that we are planning to close the database by the end of march.
  • EORTC-1647 (angio. retrospective): retrospective evaluation of adjuvant chemotherapy in angiosarcoma.
    (project leader: robin jones)
    Research project approved: 23 aug. 2016
    The primary objective of the study will be to evaluate the activity of adjuvant chemotherapy in angiosarcoma patients and to potentially guide the design of a prospective randomized study.
    Several sites (around 41) from the STBSG are planning to contribute patient data from their clinical practice.

FP7 EUROSARC – European Clinical Trials in Rare Sarcomas within an integrated translational trial network. EUROSARC aims to validate novel local and systemic treatment strategies in localized phase sarcomas, and innovative targeted therapies in advanced phase sarcomas based on the scientific understanding of molecular alterations driving the tumors. Several clinical trials are involved including EORTC trial 62092-22092-STRASS A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with Retroperitoneal sarcomas.

FP7 EEC EURO EWING – International Clinical Trials to Improve Survival from Ewing Sarcoma. EEC EURO EWING aims to improve treatment outcomes for patients with Ewing sarcoma, a rare cancer. The program comprises two clinical trials testing different chemotherapy treatments for this rare disease: trial EORTC 1402 “International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing’s Sarcoma Family of Tumours – Euro Ewing 2012” and trial EORTC 1403 “International Randomised Controlled Trial of Chemotherapy for the treatment of Recurrent and Primary Refractory Ewing Sarcoma – rEECur”.

European Reference Networks (ERN) for rare solid tumours (EURACAN). EURACAN is involving references centers in Europe covering ten types of rare cancers. EURACAN will improve patient cares and facilitate research in rare cancers. EORTC is providing the clinical research infrastructure. (No website available yet)

Research Group

Group documents
  • Chair

    Winan van Houdt

    The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis

    Amsterdam, Netherlands

  • Secretary

    Silvia Stacchiotti

    Fondazione IRCCS Istituto Nazionale dei Tumori

    Milano, Italy

  • Treasurer

    Jean-Yves Blay

    Centre Leon Berard

    Lyon, France


  • J. Bovée - Leiden, NL

    Chair Pathology and Translational Research

    Leiden University Medical Centre-Laboratory

  • S. Ford - Birmingham, GB

    Chair Local Treatment

    UHB, Queen Elisabeth Medical Centre

  • A. Dufresne - Lyon, FR

    Chair Systemic Treatment

    Centre Leon Berard

  • W. Kunz - Muenchen, DE

    Chair Imaging Subcommittee

    Ludwig-Maximilians-Universitaet Muenchen - Campus Grosshadern

  • O. Husson - Amsterdam, NL

    Chair Quality of Life Subcommittee

    The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis

  • G. Marquina - Madrid, ES

    Young and ECI representative

    Hospital Universitario San Carlos

Go to Top